New pharma tariffs are pushing biotech firms to consider voluntary pricing deals with the Trump administration for exemptions, Axios reports
Importance
Level 1
- Smaller and midsize companies say they lack the scale and financial flexibility of larger drugmakers to cut prices or reshore production, while carveouts for orphan drugs and cell and gene therapies may soften the impact for some.